Boule Diagnostics AB - Asset Resilience Ratio

Latest as of June 2025: 4.94%

Boule Diagnostics AB (BOUL) has an Asset Resilience Ratio of 4.94% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check BOUL capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

Skr23.00 Million
≈ $2.48 Million USD Cash + Short-term Investments

Total Assets

Skr465.40 Million
≈ $50.08 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2010–2024)

This chart shows how Boule Diagnostics AB's Asset Resilience Ratio has changed over time. See net asset quality index of Boule Diagnostics AB to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Boule Diagnostics AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Boule Diagnostics AB (BOUL) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr23.00 Million 4.94%
Short-term Investments Skr0.00 0%
Total Liquid Assets Skr23.00 Million 4.94%

Asset Resilience Insights

  • Limited Liquidity: Boule Diagnostics AB maintains only 4.94% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Boule Diagnostics AB Industry Peers by Asset Resilience Ratio

Compare Boule Diagnostics AB's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Medacta Group SA
SW:MOVE
Medical Devices 0.86%
Double Medical Technology Inc
SHE:002901
Medical Devices 12.59%
Shenzhen New Industries Biomedical
SHE:300832
Medical Devices 9.95%
Jafron Biomedical Co Ltd
SHE:300529
Medical Devices 39.15%
Sinocare Inc
SHE:300298
Medical Devices 3.53%
Xiangyu Medical Co. Ltd. A
SHG:688626
Medical Devices 1.53%
INKON Life Technology Co Ltd
SHE:300143
Medical Devices 5.73%
HOB Biotech Group Corp Ltd
SHG:688656
Medical Devices 2.62%

Annual Asset Resilience Ratio for Boule Diagnostics AB (2010–2024)

The table below shows the annual Asset Resilience Ratio data for Boule Diagnostics AB.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 4.48% Skr26.43 Million
≈ $2.84 Million
Skr590.20 Million
≈ $63.51 Million
-0.45pp
2023-12-31 4.93% Skr37.23 Million
≈ $4.01 Million
Skr755.11 Million
≈ $81.26 Million
-1.80pp
2022-12-31 6.73% Skr51.11 Million
≈ $5.50 Million
Skr759.96 Million
≈ $81.78 Million
+6.49pp
2021-12-31 0.24% Skr1.36 Million
≈ $146.36K
Skr572.03 Million
≈ $61.56 Million
+1.04pp
2020-12-31 -0.80% Skr-3.83 Million
≈ $-411.85K
Skr479.71 Million
≈ $51.62 Million
+3.58pp
2019-12-31 -4.38% Skr-25.70 Million
≈ $-2.77 Million
Skr586.87 Million
≈ $63.16 Million
-2.21pp
2018-12-31 -2.17% Skr-10.86 Million
≈ $-1.17 Million
Skr500.85 Million
≈ $53.90 Million
-25.98pp
2017-12-31 23.81% Skr99.16 Million
≈ $10.67 Million
Skr416.49 Million
≈ $44.82 Million
+11.57pp
2016-12-31 12.24% Skr44.59 Million
≈ $4.80 Million
Skr364.33 Million
≈ $39.21 Million
-30.74pp
2010-12-31 42.98% Skr88.58 Million
≈ $9.53 Million
Skr206.11 Million
≈ $22.18 Million
--
pp = percentage points

About Boule Diagnostics AB

ST:BOUL Sweden Medical Devices
Market Cap
$13.37 Million
Skr124.27 Million SEK
Market Cap Rank
#26319 Global
#560 in Sweden
Share Price
Skr3.20
Change (1 day)
-3.03%
52-Week Range
Skr3.15 - Skr10.30
All Time High
Skr74.05
About

Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clini… Read more